Cost-effectiveness analysis favors epoetin alfa to front-loaded regimens of darbepoetin alfa and dominates every other week dosing of darbepoetin alfa.

被引：0

作者：

Frame, D

Fastenau, JM

Piech, CT

机构：

[1] Rush Presbyterian St Lukes Med Ctr, Dept Pharm, Chicago, IL USA

[2] Ortho Biotech Prod LP, Clin Affairs, Bridgewater, NJ USA

来源：

BLOOD | 2003年 / 102卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5776

引用

页码：511B / 511B

页数：1

共 50 条

[21] A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer
Schwartzberg, LS
Yee, LK
Senecal, FM
Charu, V
Tomita, D
Wallace, J
Rossi, G
ONCOLOGIST, 2004, 9 (06): : 696 - 707
[22] Differences in treatment practice, response rates and cost of Epoetin alfa and Darbepoetin alfa treatment for anemic cancer patients: A retrospective analysis from Sweden
Persson, U
Borg, S
Jansson, S
Ekman, T
Franksson, L
Friesland, S
Larsson, AM
VALUE IN HEALTH, 2004, 7 (06) : 681 - 681
[23] The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients
AlKharboush, Hanan
Alshehri, Fatimah
Alatwi, Ibrahim
Al Karni, Khaled
Alatawi, Abdurahman
Hamdan, Ahmed M.
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (12)
[24] Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease
Suranyi, MG
Lindberg, JS
Navarro, J
Elias, C
Brenner, RM
Walker, R
AMERICAN JOURNAL OF NEPHROLOGY, 2003, 23 (02) : 106 - 111
[25] A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients
Mahajan, S
Boulton, H
Gokal, P
JOURNAL OF NEPHROLOGY, 2004, 17 (05) : 687 - 692
[26] Strategy feasibility of darbepoetin alfa administration every other week: 2005-2007 experience in a dialysis unit
Rottembourg, Jacques B.
Dansaert, Aurelie
NEPHROLOGIE & THERAPEUTIQUE, 2011, 7 (07): : 549 - 557
[27] Comparing the cost-effectiveness of 3 mcg/kg q2w darbepoetin alfa with standard dose epoetin alfa for anemia management in chemotherapy-treated cancer patients in united states
Glaspy, J
Tchekmedyian, N
Gupta, S
VALUE IN HEALTH, 2002, 5 (06) : 543 - 543
[28] A randomized, active-control, pilot trial of front loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease
Glaspy, JA
Jadeja, JS
Justice, G
Fleishman, A
Rossi, G
Colowick, AB
CANCER, 2003, 97 (05) : 1312 - 1320
[29] Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration
Toto, RD
Pichette, V
Navarro, J
Brenner, R
Carroll, W
Liu, W
Roger, S
AMERICAN JOURNAL OF NEPHROLOGY, 2004, 24 (04) : 453 - 460
[30] Incremental cost-effectiveness ratio of darbepoetin alfa (Aranesp®) in the treatment of chemotherapy-induced anemia in lung cancer patients
Borget, I
Tilleul, P.
Joly, A. C.
Chouaid, C.
VALUE IN HEALTH, 2006, 9 (06) : A278 - A279

← 1 2 3 4 5 →